N	O
-	O
carbamylglutamate	O
enhancement	O
of	O
ureagenesis	O
leads	O
to	O
discovery	O
of	O
a	O
novel	O
deleterious	O
mutation	O
in	O
a	O
newly	O
defined	O
enhancer	O
of	O
the	O
NAGS	O
gene	O
and	O
to	O
effective	O
therapy	O
.	O


N	O
-	O
acetylglutamate	O
synthase	O
(	O
NAGS	O
)	O
catalyzes	O
the	O
conversion	O
of	O
glutamate	O
and	O
acetyl	O
-	O
CoA	O
to	O
NAG	O
,	O
the	O
essential	O
allosteric	O
activator	O
of	O
carbamyl	O
phosphate	O
synthetase	O
I	O
,	O
the	O
first	O
urea	O
cycle	O
enzyme	O
in	O
mammals	O
.	O


A	O
17	O
-	O
year	O
-	O
old	O
female	O
with	O
recurrent	O
hyperammonemia	O
attacks	O
,	O
the	O
cause	O
of	O
which	O
remained	O
undiagnosed	O
for	O
8	O
years	O
in	O
spite	O
of	O
multiple	O
molecular	O
and	O
biochemical	O
investigations	O
,	O
showed	O
markedly	O
enhanced	O
ureagenesis	O
(	O
measured	O
by	O
isotope	O
incorporation	O
)	O
in	O
response	O
to	O
N	O
-	O
carbamylglutamate	O
(	O
NCG	O
)	O
.	O


This	O
led	O
to	O
sequencing	O
of	O
the	O
regulatory	O
regions	O
of	O
the	O
NAGS	O
gene	O
and	O
identification	O
of	O
a	O
deleterious	O
single	O
-	O
base	O
substitution	O
in	O
the	O
upstream	O
enhancer	O
.	O


The	O
homozygous	O
mutation	O
(	O
c	O
.	O
-	O
3064C	O
>	O
A	O
)	O
,	O
affecting	O
a	O
highly	O
conserved	O
nucleotide	O
within	O
the	O
hepatic	O
nuclear	O
factor	O
1	O
(	O
HNF	O
-	O
1	O
)	O
binding	O
site	O
,	O
was	O
not	O
found	O
in	O
single	O
nucleotide	O
polymorphism	O
databases	O
and	O
in	O
a	O
screen	O
of	O
1	O
,	O
086	O
alleles	O
from	O
a	O
diverse	O
population	O
.	O


Functional	O
assays	O
demonstrated	O
that	O
this	O
mutation	O
decreases	O
transcription	O
and	O
binding	O
of	O
HNF	O
-	O
1	O
to	O
the	O
NAGS	O
gene	O
,	O
while	O
a	O
consensus	O
HNF	O
-	O
1	O
binding	O
sequence	O
enhances	O
binding	O
to	O
HNF	O
-	O
1	O
and	O
increases	O
transcription	O
.	O


Oral	O
daily	O
NCG	O
therapy	O
restored	O
ureagenesis	O
in	O
this	O
patient	O
,	O
normalizing	O
her	O
biochemical	O
markers	O
,	O
and	O
allowing	O
discontinuation	O
of	O
alternate	O
pathway	O
therapy	O
and	O
normalization	O
of	O
her	O
diet	O
with	O
no	O
recurrence	O
of	O
hyperammonemia	O
.	O


Inc	O
.	O
